Artikel: Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults
2017
Abstract: High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This ... ...
| Abstract | High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This analysis models the public health impact and cost-effectiveness (CE) of these vaccines for 50â64year-olds.Markov model CE analysis compared 5 strategies in 50â64year-olds: no vaccination; only standard-dose IIV3 offered (SD-IIV3 only), only quadrivalent influenza vaccine offered (SD-IIV4 only); high-risk patients receiving HD-IIV3, others receiving SD-IIV3 (HD-IIV3 & SD-IIV3); and high-risk patients receiving HD-IIV3, others receiving SD-IIV4 (HD-IIV3 & SD-IIV4). In a secondary analysis, RIV replaced HD-IIV3. Parameters were obtained from U.S. databases, the medical literature and extrapolations from VE estimates. Effectiveness was measured as 3%/year discounted quality adjusted life year (QALY) losses avoided.The least expensive strategy was SD-IIV3 only, with total costs of $99.84/person. The SD-IIV4 only strategy cost an additional $0.91/person, or $37,700/QALY gained. The HD-IIV3 & SD-IIV4 strategy cost $1.06 more than SD-IIV4 only, or $71,500/QALY gained. No vaccination and HD-IIV3 & SD-IIV3 strategies were dominated. Results were sensitive to influenza incidence, vaccine cost, standard-dose VE in the entire population and high-dose VE in high-risk patients. The CE of RIV for high-risk patients was dependent on as yet unknown parameter values.Based on available data, using high-dose influenza vaccine or RIV in middle-aged, high-risk patients may be an economically favorable vaccination strategy with public health benefits. Clinical trials of these vaccines in this population may be warranted. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Schlagwörter | adults ; clinical trials ; cost effectiveness ; databases ; influenza ; influenza vaccination ; influenza vaccines ; models ; patients ; public health ; quality-adjusted life year ; risk ; United States | ||||||||||
| Sprache | Englisch | ||||||||||
| Umfang | p. . | ||||||||||
| Erscheinungsort | Elsevier Ltd | ||||||||||
| Dokumenttyp | Artikel | ||||||||||
| Anmerkung | Pre-press version | ||||||||||
| ZDB-ID | 605674-x | ||||||||||
| ISSN | 1873-2518 ; 0264-410X | ||||||||||
| ISSN (online) | 1873-2518 | ||||||||||
| ISSN | 0264-410X | ||||||||||
| DOI | 10.1016/j.vaccine.2017.07.069 | ||||||||||
| Signatur |
|
||||||||||
| Datenquelle | NAL Katalog (AGRICOLA) |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 1930: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 458: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.